MDT

84.21

+0.41%↑

VEEV

227.67

+3.34%↑

A

106.91

+1.84%↑

WBA

11.03

+0.46%↑

CHE

546.34

-6.7%↓

MDT

84.21

+0.41%↑

VEEV

227.67

+3.34%↑

A

106.91

+1.84%↑

WBA

11.03

+0.46%↑

CHE

546.34

-6.7%↓

MDT

84.21

+0.41%↑

VEEV

227.67

+3.34%↑

A

106.91

+1.84%↑

WBA

11.03

+0.46%↑

CHE

546.34

-6.7%↓

MDT

84.21

+0.41%↑

VEEV

227.67

+3.34%↑

A

106.91

+1.84%↑

WBA

11.03

+0.46%↑

CHE

546.34

-6.7%↓

MDT

84.21

+0.41%↑

VEEV

227.67

+3.34%↑

A

106.91

+1.84%↑

WBA

11.03

+0.46%↑

CHE

546.34

-6.7%↓

Search

United Therapeutics Corp

Closed

SectorHealthcare

295.8 0.9

Overview

Share price change

24h

Current

Min

289.05

Max

297.62

Key metrics

By Trading Economics

Income

-7.8M

301M

Sales

-13M

736M

P/E

Sector Avg

11.884

57.333

EPS

6.19

Profit margin

40.943

Employees

1,305

EBITDA

6.3M

424M

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+29.27% upside

Dividends

By Dow Jones

Next Earnings

30 Apr 2025

Market Stats

By TradingEconomics

Market Cap

-3.4B

13B

Previous open

294.9

Previous close

295.8

Technical Score

By Trading Central

Confidence

Very Strong Bullish Evidence

United Therapeutics Corp Chart

Past performance is not a reliable indicator of future results.

Related News

7 Oct 2024, 15:14 UTC

Major Market Movers

Liquidia Shares Rise After Supreme Court Rejects United Therapeutics' Patent Appeal

28 Jan 2025, 10:30 UTC

Top News

Drug Companies Raise Prices on More Than 800 Drugs in January -- WSJ

Peer Comparison

Price change

United Therapeutics Corp Forecast

Price Target

By TipRanks

29.27% upside

12 Months Forecast

Average 383.18 USD  29.27%

High 460 USD

Low 293 USD

Based on 11 Wall Street analysts offering 12 month price targets forUnited Therapeutics Corp - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

11 ratings

8

Buy

3

Hold

0

Sell

Technical Score

By Trading Central

285.09 / 298.295Support & Resistance

Short Term

Very Strong Bullish Evidence

Intermediate Term

Weak Bearish Evidence

Long Term

Bearish Evidence

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About United Therapeutics Corp

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.